Adis adds PRIME status to AdisInsight drug profiles.
In 2016, the European Medicines Agency launched PRIME – a program to enhance support for the development of medicines that target an unmet medical need. This voluntary program is based on enhanced interaction and early dialogue with developers of promising medicine, to optimise development plans and speed up evaluation so that these medicines can reach patients earlier.
In the latest round of enhancements to AdisInsight, PRIME has been added both to the development status of relevant drug profiles, and also as a search facet in the left-hand menu, enabling users to pinpoint drugs with this priority status.
The addition of PRIME status in AdisInsight, coupled with existing coverage of FastTrack in the USA, provides platform users with insight into those drug development programs with accelerated regulatory status that have the opportunity to reach the market faster than those traversing normal regulatory pathways.
For more information, or for a walk-through of this functionality, please get in touch with the AdisInsight team.